Epidemiological studies are usually conducted in the general population in adults without complications or pathology at baseline. The results obtained are therefore often better designed for primary prevention use. The prediction of mortality risk in patients with complications and requiring hospital follow-up is less well known.
The study purpose is to determine a mortality risk profile in a hospital cohort of patients with pathologies associated with metabolic diseases.
Today the "multimaker" scores based on a panel of biomarkers - have significantly improved the discriminating power of prediction models existing in many pathologies. It is no longer a single biomarker that can improve risk prediction but a complete and cross-sectional profile that is sought after. We aim to establish a personalised mortality risk profile by combining clinical and biological parameters including metabolomics, genetics, transcriptomics and epigenomics by high throughput screening of biological samples.
Diabetic: antecedent - treatment - or glycemia> = 1.26 g / dl - or HbA1C> = 6.5% and or
Obese: BMI> = 30 and or
Metabolic syndrome defined AND
Patient having given written consent to participate in the study or collection of the consent of the witness
Unscheduled hospitalization less than 3 months old
Cytotoxic chemotherapy
Radiotherapy
HIV and / or HCV and / or active HBV infection
patients with pathologies associated with metabolic disease
Cohort
Prospective
Not listed
number of death
The number of patients dead according to national database
Occurrence of macrovascular complications (composite criteria)
composite criteria: cardiovascular death, myocardial infarction, stroke, coronary revascularization, peripheral revascularization, amputation)
hospitalization for heart failure
The number of patients that has been hospitalized for heart failure since the end of the study according to national database
Occurence of renal microvasculare complications (composite criteria)
composite criteria: renal transplantation, dialysis, GFR \>60, Albuminuria
Occurrence of liver complications(composite endpoint)
composite endpoint: hepatic fibrosis, cirrhosis, HCC, death from liver
Click on the lead sponsor to view all of their trials.
